Concepedia

Joel Morris

JM

15

Publications

2.8K

Citations

14

H-Index

2004

Active since

Affiliations

National Cancer Institute(Current)

Center for Cancer Research

Frederick National Laboratory for Cancer Research

Leidos (United States)

National Cancer Institute

Joel Morris is an author at National Cancer Institute specializing in medicine, drug discovery, and molecular biology.

ORCID

Top concepts

Publications per year

2004–2024

15

Publications

15

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

William C. Reinhold, Margot Sunshine, Hongfang Liu et al. · Cancer Research · 2012 · 903 citations · Full text

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-yin N. Huang, Amèlie Renaud et al. · Molecular Cancer Therapeutics · 2013 · 745 citations · Full text

, , +15

Comprehensive characterization of the Published Kinase Inhibitor Set

Jonathan M. Elkins, Vita Fedele, M. Szklarz et al. · Nature Biotechnology · 2015 · 338 citations · Full text

Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

Junko Murai, Yiping Zhang, Joel Morris et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 278 citations · Full text

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

Eric C. Polley, Mark W. Kunkel, David M. Evans et al. · JNCI Journal of the National Cancer Institute · 2016 · 164 citations · Full text

Rows per page

1–5 of 15